Literature DB >> 26166722

Secondary Involvement of the Adnexa and Uterine Corpus by Carcinomas of the Uterine Cervix: A Detailed Morphologic Description.

Carolina Reyes1, Rajmohan Murali, Kay J Park.   

Abstract

Cervical carcinoma infrequently involves the uterine corpus or adnexa. Metastatic adenocarcinoma (AC) to the ovaries can be difficult to distinguish from primary ovarian tumors, and metastatic squamous cell carcinoma (SCC) to these sites has not been well described. Our aim was to provide a detailed description of the morphologic patterns of adnexal and corpus involvement by cervical carcinoma. Cases were identified over a 15-yr period and the following features were recorded: visible lesion, depth of invasion, lymphovascular invasion, and patterns of spread. Only usual human papillomavirus-associated tumors were included. Twenty cases with available slides were identified (2 in situ and 8 invasive SCC; 10 AC); 17 had visible lesions, usually with deep cervical and lymphovascular invasion. Sixteen involved the corpus (1 in situ, 7 SCC, 8 AC), all colonizing endometrium and 10 invading myometrium. SCC involved the ovary and fallopian tube in 4 and 6 cases, respectively, whereas AC involved the ovary in 4 (2 unilateral, 2 bilateral) and the tube in 8 cases. SCC in the ovary usually showed parenchymal invasion, and parenchymal and mucosal involvement in the tube. AC in the ovary ranged from small nodules to confluent expansile growth, whereas in the tube it often showed mucosal colonization mimicking a primary tubal process. Adnexal metastasis of cervical carcinoma is rare and usually coexists with endometrial and myometrial extension from the cervix. Both squamous and ACs can colonize tubal and endometrial mucosa; AC in particular can mimic primaries at those sites. Bilaterality is not a common feature of metastatic endocervical AC.

Entities:  

Mesh:

Year:  2015        PMID: 26166722      PMCID: PMC4976698          DOI: 10.1097/PGP.0000000000000206

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  27 in total

1.  Ovarian metastasis in carcinoma of the uterine cervix.

Authors:  Muneaki Shimada; Junzo Kigawa; Ryuichiro Nishimura; Satoshi Yamaguchi; Kazuo Kuzuya; Toru Nakanishi; Mitsuaki Suzuki; Tsunekazu Kita; Tsuyoshi Iwasaka; Naoki Terakawa
Journal:  Gynecol Oncol       Date:  2005-11-21       Impact factor: 5.482

Review 2.  Invasive adenocarcinoma and related tumors of the uterine cervix.

Authors:  R H Young; R E Scully
Journal:  Semin Diagn Pathol       Date:  1990-08       Impact factor: 3.464

3.  A comparison of ovarian metastasis between squamous cell carcinoma and adenocarcinoma of the uterine cervix.

Authors:  T Nakanishi; K Wakai; H Ishikawa; A Nawa; Y Suzuki; S Nakamura; K Kuzuya
Journal:  Gynecol Oncol       Date:  2001-09       Impact factor: 5.482

4.  Ovarian squamous cell carcinoma which metastasized 8 years after cervical conization for early microinvasive cervical cancer: a case report.

Authors:  Takao Hidaka; Akitoshi Nakashima; Toru Hasegawa; Kazuhiro Nomoto; Shin Ishizawa; Koichi Tsuneyama; Yasuo Takano; Shigeru Saito
Journal:  Jpn J Clin Oncol       Date:  2011-04-05       Impact factor: 3.019

Review 5.  Glandular lesions of the uterine cervix.

Authors:  R J Zaino
Journal:  Mod Pathol       Date:  2000-03       Impact factor: 7.842

Review 6.  Metastatic ovarian tumors: a review of 64 cases.

Authors:  Namiko Yada-Hashimoto; Toshiya Yamamoto; Shoji Kamiura; Hozumi Seino; Hiroki Ohira; Keisuke Sawai; Tadashi Kimura; Fumitaka Saji
Journal:  Gynecol Oncol       Date:  2003-05       Impact factor: 5.482

7.  The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites.

Authors:  B M Ronnett; R J Kurman; B M Shmookler; P H Sugarbaker; R H Young
Journal:  Am J Surg Pathol       Date:  1997-10       Impact factor: 6.394

8.  Cervical squamous cell carcinoma in situ with intraepithelial extension to the upper genital tract and invasion of tubes and ovaries: report of a case with human papilloma virus analysis.

Authors:  M R Pins; R H Young; C P Crum; I H Leach; R E Scully
Journal:  Int J Gynecol Pathol       Date:  1997-07       Impact factor: 2.762

9.  Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential.

Authors:  B M Ronnett; R J Kurman; C M Zahn; B M Shmookler; K A Jablonski; M E Kass; P H Sugarbaker
Journal:  Hum Pathol       Date:  1995-05       Impact factor: 3.466

10.  Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification.

Authors:  Anna V Yemelyanova; Russell Vang; Kara Judson; Lee-Shu-Fune Wu; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2008-01       Impact factor: 6.394

View more
  10 in total

1.  Clinicopathological characteristics of fallopian tube metastases from primary endometrial, cervical, and nongynecological malignancies: a single institutional experience.

Authors:  Kiyong Na; Hyun-Soo Kim
Journal:  Virchows Arch       Date:  2017-07-13       Impact factor: 4.064

Review 2.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

Review 3.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

4.  Fallopian Tube Mucosal Involvement in Cervical Gastric-type Adenocarcinomas: Report of a Series With Discussion of the Distinction From Synchronous In Situ Tubal Lesions.

Authors:  Simon Rajendran; Yaser Hussein; Kay J Park; W Glenn McCluggage
Journal:  Am J Surg Pathol       Date:  2018-06       Impact factor: 6.394

Review 5.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

6.  Clinical, Morphologic, and Molecular Features Associated With Ovarian Metastases From Pattern A Endocervical Adenocarcinomas.

Authors:  Jacqueline Feinberg; Anjelica Hodgson; Nadeem R Abu-Rustum; Kara Long Roche; Kay J Park
Journal:  Am J Surg Pathol       Date:  2022-04-01       Impact factor: 6.394

7.  Analysis of Clinicopathological Features of Cervical Mucinous Adenocarcinoma with a Solitary Ovarian Metastatic Mass as the First Manifestation.

Authors:  Shuanghuan Liu; Yunquan Guo; Bin Li; Huijuan Zhang; Rong Zhang; Shan Zheng
Journal:  Cancer Manag Res       Date:  2020-09-24       Impact factor: 3.989

8.  Ovarian Mesonephric-like Adenocarcinoma With Multifocal Microscopic Involvement of the Fimbrial Surface: Potential for Misdiagnosis of Tubal Intraepithelial Metastasis as Serous Tubal Intraepithelial Carcinoma Associated With Ovarian High-grade Serous Carcinoma.

Authors:  Hyunjin Kim; Go Eun Bae; Yoon Yang Jung; Hyun-Soo Kim
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

9.  Adenocarcinoma of the cervix involving the fallopian tube mucosa: report of a case.

Authors:  Chelsey D Deel; Richard A Allen; Laura L Holman; Rosemary E Zuna
Journal:  Diagn Pathol       Date:  2016-08-17       Impact factor: 2.644

Review 10.  Endocervical Adenocarcinoma, Gross Examination, and Processing, Including Intraoperative Evaluation: Recommendations From the International Society of Gynecological Pathologists.

Authors:  Carlos Parra-Herran; Anais Malpica; Esther Oliva; Gian Franco Zannoni; Pedro T Ramirez; Joseph T Rabban
Journal:  Int J Gynecol Pathol       Date:  2021-03-01       Impact factor: 3.326

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.